Literature DB >> 23765753

Total testosterone and sex hormone-binding globulin are significantly associated with metabolic syndrome in middle-aged and elderly men.

K-Y Chin1, S Ima-Nirwana, I N Mohamed, A Aminuddin, W Z W Ngah.   

Abstract

Testosterone and sex hormone-binding globulin (SHBG) have been shown to be associated with metabolic syndrome (MS) in men. This study aimed at validating these relationships in a group of middle-aged and elderly men and assessing their strength of association to MS. A cross-sectional study of 332 Malaysian men aged 40 years and above was conducted. The blood of subject was collected under fasting condition for determination of testosterone, SHBG, glucose and lipid levels. Their medical history, smoking and alcohol consumption status, waist circumference (WC), body mass index (BMI) and blood pressure (BP) were recorded. All testosterone and SHBG levels were significantly reduced in MS subjects compared to non-MS subjects (p<0.05). Testosterone and SHBG were correlated significantly with most of the MS indicators without adjustments. In multiple regression analysis, the triglyceride level was the only MS indicator that was significantly, inversely and independently associated with all testosterone measurements and SHBG (p<0.05). Waist circumference was significantly and negatively associated with SHBG level (p<0.05) though not independent of BMI. Total testosterone and SHBG were significantly and inversely associated with the presence of MS. Testosterone and SHBG are potential intervention targets for the prevention of MS in men. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23765753     DOI: 10.1055/s-0033-1345164

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  7 in total

1.  Physicians' attitudes towards androgen replacement therapy for male and female sexual dysfunction.

Authors:  L Lowenstein; A Shechter; H Porst; F Tripodi; Y Reisman
Journal:  Int J Impot Res       Date:  2016-02-11       Impact factor: 2.896

Review 2.  Testosterone replacement therapy and cardiovascular risk.

Authors:  Thiago Gagliano-Jucá; Shehzad Basaria
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

3.  The association between bone health indicated by calcaneal quantitative ultrasound and metabolic syndrome in Malaysian men.

Authors:  Kok-Yong Chin; Soelaiman Ima-Nirwana; Isa Naina Mohamed; Fairus Ahmad; Elvy Suhana Mohd Ramli; Amilia Aminuddin; Wan Zurinah Wan Ngah
Journal:  J Diabetes Metab Disord       Date:  2015-03-07

4.  Is serum sex hormone-binding globulin a dominant risk factor for metabolic syndrome?

Authors:  Yi-Hong Yang; Ming-Jia Zhao; Shan-Jie Zhou; Wen-Hong Lu; Xiao-Wei Liang; Cheng-Liang Xiong; Chang-Chun Wan; Xue-Jun Shang; Yi-Qun Gu
Journal:  Asian J Androl       Date:  2015 Nov-Dec       Impact factor: 3.285

5.  Association of total testosterone, free testosterone, bioavailable testosterone, sex hormone-binding globulin, and hypertension.

Authors:  Qingtao Yang; Zhenjie Li; Wencai Li; Liang Lu; Haoqiang Wu; Yiyi Zhuang; Kusheng Wu; Xuxia Sui
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 6.  Transdermal testosterone replacement therapy in men.

Authors:  M Iftekhar Ullah; Daniel M Riche; Christian A Koch
Journal:  Drug Des Devel Ther       Date:  2014-01-09       Impact factor: 4.162

Review 7.  Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome.

Authors:  Abdulmaged M Traish; Vanessa Johansen
Journal:  World J Mens Health       Date:  2018-07-03       Impact factor: 5.400

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.